BiotechTube

Tarceva (erlotinib HCl, OSI-774)

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer

Trial Timeline

Nov 29, 2001 → Jan 15, 2004

NCT ID
NCT00040183

About Tarceva (erlotinib HCl, OSI-774)

Tarceva (erlotinib HCl, OSI-774) is a phase 3 stage product being developed by Astellas Pharma for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00040183. Target conditions include Pancreatic Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00040183Phase 3Completed

Competing Products

20 competing products in Pancreatic Cancer

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
pemetrexedEli LillyPhase 2
52
mFOLFIRINOX + RamucirumabEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
enzastaurin + gemcitabineEli LillyPhase 2
52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
33
RamucirumabEli LillyPhase 1/2
41
GEMZAR + ALIMTAEli LillyPhase 3
77
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
52
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
33
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
33
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
52
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
33
ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + CapecitabineAstellas PharmaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85